14 Results for "

RIG-I signaling pathway

" in MedChemExpress (MCE) Product Catalog:
Products (14)

14 Results for "RIG-I signaling pathway" in MCE Product Catalog:

8
8 Publications Verification
Cat. No.: HY-P1934
CAS No.: 14705-60-3
Synonyms: Cyclo(phenylalanylprolyl); A-64863
Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)) is a quorum-sensing molecule of Vibrio vulnificus that specifically interacts with RIG-I, inhibiting RIG-I polyubiquitination, suppressing IRF-3 activation, and reducing type I interferon production. Cyclo(Phe-Pro) enhances susceptibility to HCV and influenza virus and also alleviates plant aluminum toxicity stress. The mechanism of Cyclo(Phe-Pro) involves the regulation of host immune signaling pathways, bacterial virulence gene expression, and plant antioxidant systems, making it a promising candidate for research in viral infections, bacterial virulence regulation, and agricultural stress resistance .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-126675A
CAS No.: 2241300-51-4
Purity:  99.94%
Research Areas:  

Inflammation/Immunology

AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-126675
CAS No.: 2241300-50-3
Purity:  99.68%
Research Areas:  

Inflammation/Immunology

AS2863619 free base is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 free base targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 free base also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 free base exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 free base can be applied to research in related fields such as periodontitis-induced bone defects .
loading...
    loading...
Cat. No.: HY-160229
Synonyms: R-1075 sodium
ssRNA40 sodium (R-1075 sodium) is a single-stranded RNA40 derived from HIV-1. ssRNA40 sodium activates the TLR7, TLR8, TLR2, RIG-I, MDA5, MyD88, Caspase-3, IRE1α, NLRP3 inflammasome and IRF7 signaling pathways. ssRNA40 sodium alters mRNA expression in neutrophils, induces pro-inflammatory cytokines, ROS, autophagy (autophagy), pyroptosis (pyroptosis), neuronal death, neurodegeneration, aggregate formation and NK cell activation. ssRNA40 sodium activates the expression of CD62L, CD11b, CD69, MX1, OAS1, ATG7, LC3B and XBP1 in immune cell and neuronal populations. ssRNA40 sodium causes cortical neuron loss and axonal damage in mice in a TLR7-dependent manner. ssRNA40 sodium can be used in research on HIV-1 infection, neurodegeneration, COVID-19 and HIV-associated neurological disorders .
loading...
    loading...
Cat. No.: HY-N0891
CAS No.: 115810-12-3
Synonyms: Tubeimoside-B
Tubeimoside II is an orally active triterpenoid saponin and antiviral agent that binds to PACT/PRKRA with Kd values of 5.37 μM and 133.1 μM, respectively. Tubeimoside II inhibits oxidase-dependent EGFR activation and reduces TGF-β1-induced oxidative stress. Tubeimoside II activates the RIG-I signaling pathway and increases IFN-β secretion. Tubeimoside II suppresses TPA-induced ear edema, mouse sarcoma 180 growth, and TPA-induced skin tumor formation. Tubeimoside II exerts broad-spectrum antiviral activity against SARS-CoV-2, HCoV-OC43, and IAV-H1N1/FM1. Tubeimoside II can be used in research related to retinoblastoma, respiratory viral infections, skin tumors, and sarcoma 180 .
loading...
    loading...
Cat. No.: HY-145121
CAS No.: 2871872-79-4
Purity:  99.93%
DS96432529 is an orally active CDK8 inhibitor with an IC50 of 33 nM. DS96432529 enhances ALPase activity, with an EC200 of 63 nM. DS96432529 inhibits TNF-α-induced activation of the RLR signaling pathway, activates mitophagy, accelerates mineralized nodule formation, and suppresses the proliferation of periodontal ligament stem cells. DS96432529 promotes bone formation, alleviates ligation-induced alveolar bone loss, and increases bone mineral density in ovariectomized animal models. DS96432529 can be used in studies related to periodontitis and osteoporosis .
loading...
    loading...
Cat. No.: HY-177817
Research Areas:  

Infection

CL9 sodium, a RIG-I-specific RNA aptamer, activates signaling pathways for IFNβ produciton and efficiently blocks viral replication. RIG-I is a cytosolic receptor for non-self RNA that mediates immune responses against viral infections through IFNα/β prod
loading...
    loading...
Cat. No.: HY-N0891R
CAS No.: 115810-12-3
Synonyms: Tubeimoside-B (Standard)
Tubeimoside II (Standard) (Tubeimoside-B (Standard)) is the analytical standard of Tubeimoside II (HY-N0891). This product is intended for research and analytical applications. Tubeimoside II is an orally active triterpenoid saponin and antiviral agent that binds to PACT/PRKRA with Kd values of 5.37 μM and 133.1 μM, respectively. Tubeimoside II inhibits oxidase-dependent EGFR activation and reduces TGF-β1-induced oxidative stress. Tubeimoside II activates the RIG-I signaling pathway and increases IFN-β secretion. Tubeimoside II suppresses TPA-induced ear edema, mouse sarcoma 180 growth, and TPA-induced skin tumor formation. Tubeimoside II exerts broad-spectrum antiviral activity against SARS-CoV-2, HCoV-OC43, and IAV-H1N1/FM1. Tubeimoside II can be used in research related to retinoblastoma, respiratory viral infections, skin tumors, and sarcoma 180 .
loading...
    loading...
Cat. No.: HY-W682115
CAS No.: 30811-80-4
Synonyms: Polycytidylic acid
Poly(C) (Polycytidylic acid) is a pleiotropic immunostimulant that specifically binds to TLR3, RIG-I and MDA5 receptors. Poly (C) recruits adaptor proteins to activate downstream signaling pathways and induce the production of type I interferons and inflammatory cytokines. Poly (C) triggers cancer cell apoptosis via the intrinsic or extrinsic caspase pathway, thereby exerting inhibitory effects on tumor growth and metastasis. Poly (C) acts as a vaccine adjuvant to modify the tumor microenvironment, regulate the expression of endothelial adhesion molecules and induce virus-like immune responses. Poly (C) can be applied to research related to melanoma, various solid tumors, hematological malignancies and autoimmune insulin-dependent diabetes mellitus .
loading...
    loading...
Cat. No.: HY-126675G
CAS No.: 2241300-51-4
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .
loading...
    loading...
Cat. No.: HY-189280
CAS No.: 2718206-92-7
Research Areas:  

Inflammation/Immunology

S-570 is an orally active selective STING antagonist. S-570 inhibits the secretion of the cytokines IFN-β and IL-6. S-570 can be used for research on inflammation .
loading...
    loading...
Cat. No.: HY-189215
CAS No.: 3087067-85-1
Anti-Influenza agent 12 is an orally active inhibitor of influenza A virus infection. Anti-Influenza agent 12 inhibits RIG-I-mediated innate immune signaling and TLR3-mediated signaling pathways. Anti-Influenza agent 12 inhibits NF-κB phosphorylation and downregulates the expression levels of IRF3, ASC, iNOS, IL-4, IL-6, and IFN-α inflammatory genes. Anti-Influenza agent 12 inhibits viral nucleoprotein (NP) and matrix protein 2 (M2) mRNA transcription and protein synthesis. Anti-Influenza agent 12 inhibits virus-induced apoptosis, reduces ROS and NO production, and maintains mitochondrial membrane potential. Anti-Influenza agent 12 exhibits broad-spectrum activity against H1N1 and H3N2 subtypes, reduces viral load, and alleviates lung tissue damage. Anti-Influenza agent 12 can be used for research on influenza A virus infection .
loading...
    loading...
Cat. No.: HY-187997
Research Areas:  

Cancer

ADAR1-IN-2 is an adenosine analog and an orally active ADAR1 inhibitor with antiproliferative activity against multiple ADAR1-dependent cancer cell lines. ADAR1-IN-2 inhibits ADAR1-mediated A‑to‑I editing of partial RNA substrates (APOBEC3D), thereby activating the RIG‑I/MDA5‑MAVS signaling pathway, inducing G0/G1 cell cycle arrest and apoptosis in tumor cells, and suppressing tumor cell migration and invasion. ADAR1-IN-2 inhibits tumor growth in DU-145 and HUCCT1 xenograft models. ADAR1-IN-2 can be used in research related to cancers such as prostate cancer and breast cancer .
loading...
    loading...
Cat. No.: HY-145121R
CAS No.: 2871872-79-4
DS96432529 (Standard) is the analytical standard of DS96432529 (HY-145121). This product is intended for research and analytical applications. DS96432529 is an orally active CDK8 inhibitor with an IC50 of 33 nM. DS96432529 enhances ALPase activity, with an EC200 of 63 nM. DS96432529 inhibits TNF-α-induced activation of the RLR signaling pathway, activates mitophagy, accelerates mineralized nodule formation, and suppresses the proliferation of periodontal ligament stem cells. DS96432529 promotes bone formation, alleviates ligation-induced alveolar bone loss, and increases bone mineral density in ovariectomized animal models. DS96432529 can be used in studies related to periodontitis and osteoporosis .
loading...
    loading...
  • 1